SCHEMBL625642

SCHEMBL625642

CCCCCC/C=C/CN

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.58
TRPV1 Q8NER1 1/20 0.58
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 2/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
TP53 P04637 1/20 0.56
CYP3A4 P08684 1/20 0.56
SOAT1 P35610 1/20 0.56
TERT O14746 3/20 0.50
PTPN1 P18031 3/20 0.50
MAPT P10636 2/20 0.50
BLM P54132 2/20 0.50
HSD17B10 Q99714 2/20 0.50
FABP4 P15090 2/20 0.50
PPARG P37231 2/20 0.50
PPARD Q03181 2/20 0.50
PPARA Q07869 2/20 0.50
GMNN O75496 1/20 0.50
USP2 O75604 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2184498 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL3455495 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL2137537 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL3128648 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL9235251 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL2137541 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL3625233 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL2184557 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL3625235 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A
SCHEMBL3623659 1.00 FAAH (0.58) FAAHTRPV1CYP1A2CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024129979-A1 METHOTREXATE TREATMENT METHODS ALDEYRA THERAPEUTICS, INC. (US) 2024-06-20 WO disclosed
US-20240197740-A1 METHOTREXATE TREATMENT METHODS ALDEYRA THERAPEUTICS, INC. 2024-06-20 US disclosed
US-11911385-B1 Methotrexate treatment methods ALDEYRA THERAPEUTICS, INC. (US) 2024-02-27 US disclosed
WO-2022204461-A1 KITS, COMPOSITIONS, AND METHODS OF TREATING HAIR LOSS ANDREWS NICK (US) 2022-09-29 WO disclosed
US-20220133697-A1 INJECTABLE FORMULATIONS ALDEYRA THERAPEUTICS, INC. 2022-05-05 US disclosed
EP-3890732-A1 INJECTABLE FORMULATIONS Aldeyra Therapeutics, Inc. (US) 2021-10-13 EP disclosed
WO-2020118045-A1 INJECTABLE FORMULATIONS ALDEYRA THERAPEUTICS, INC. (US) 2020-06-11 WO disclosed
US-10272040-B2 Liposomal formulation for ocular drug delivery NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2019-04-30 US disclosed
US-20130216606-A1 LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY SINGAPORE HEALTH SERVICES PTE LTD (SG) 2013-08-22 US disclosed
WO-2012021107-A2 A LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2012-02-16 WO disclosed
US-7789934-B2 Combination of an N-alkyl- or N,N-dialkylpolyhydroxyalkanamide and a metal soap, an alkylenebisfatty amide, or an N-alkylalkanamide; improves both flowability and lubricity, regardless of a presence or absence of a complicated pretreatment step. KABUSHIKI KAISHA KOBE SEIKO SHO (JP) 2010-09-07 US disclosed
US-20070154340-A1 Lubricant for powder metallurgy, powdery mixture for powder metallurgy, and process for producing sinter KABUSHIKI KAISHA KOBE SEIKO SHO (JP) 2007-07-05 US disclosed
US-4256903-A REACTING SULFUR DIOXIDE AND CONJUGATED DIENES IN THE PRESENCE OF A MONO OR DI-ALKENYL AMINE PHILLIPS PETROLEUM COMPANY (US) 1981-03-17 US disclosed
US-3984478-A TREATING AN UNSATURATED COMPOUND WITH CARBON MONOXIDE IN A HETEROGENEOUS CATALYST UNIVERSAL OIL PRODUCTS COMPANY (US) 1976-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10272040-B2 Liposomal formulation for ocular drug delivery PTGS2, PTGES2, PTGER2 FAAH 153/4885TRPV1 710/4885CYP1A2 465/4885
US-20220133697-A1 INJECTABLE FORMULATIONS ALDH2, CLN6, ALDH1A1 FAAH 874/4885TRPV1 2134/4885CYP1A2 298/4885
US-20130216606-A1 LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY PTGS2, PTGES2, PTGER2 FAAH 153/4885TRPV1 710/4885CYP1A2 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.